XCancer

PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer

Description:

The purpose of this study is: To validate the efficacy of multiparametric MRI, FDG-PET, RGD-PET, and PET-MR fusion imaging in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients. To identify the optimal combination parameters of MR spectroscopy, diffusion-weighted MRI, dynamic contrast-enhanced MRI, FDG-PET, and RGD-PET in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients. To compare the performances of dynamic contrast-enhanced MRI using parametric response map analysis versus those of pharmacokinetic parameters (Ktrans, kep, or Ve) in the early prediction of pathological responsiveness to neoadjuvant chemotherapy in breast cancer patients

Sponsor:

Seoul National University Hospital

Contacts:

Woo Kyung Moon, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT01190566 - Click here to see study on

ClinicalTrials.gov

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

RGD

Isotope(s):
Target(s):
  • αvβ3
Ligand Class: Small Molecules
Inclusion
  • Clinical stage IIb, IIIa, IIIb, IIIc
  • Must have measurable disease
  • Adequate, bone marrow, liver, heart, and renal function
  • Performance status of ECOG 0-2
  • * Pathologically confirmed breast cancer
Exclusion
  • Psychological disease or seizure
  • History of arrhythmia, congestive heart failure, myocardial infarct, or unstable angina
  • Active bacterial infection
  • Pregnant or lactating women
  • * Prior history of cancer besides breast cancer